About Pudee

Reliability, Responsibility and Rapidity

Founded in 2007, focus on the synthesis of small molecule compounds and the extraction of some natural compounds. We develop, produce and sell high-quality advanced intermediates and some APIs with competitive prices.
Get Appointment

Contact Info

  • Building 2, Handa Science and Technology Park
    No. 8 Pioneer Road
    High-tech Zone. Suzhou.
  • 86 512 6803 2792
    86 512 6803 2791
  • willdyhan@pudeepharm.com
    sales@pudeepharm.com

Product Details

Ixazomib,1072833-77-2

Ixazomib,1072833-77-2 | 1072833-77-2

Chemical Name: B-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]boronic acid

CAS Number: 1072833-77-2
Formula: C14H19BCl2N2O4
Molecular weight: 361.03

Product Description

Suzhou Pudee is a small and below-the-radar company that has been engaged in the research and development of advanced single molecules for nearly twenty years.

Since 2021, we started to focused on the research and development of Electronic chemicals and Aroma chemicals, Especially photoresist materials and Perfume & Fragrance materials.the electronic chemicals are used in Photoresist,MOF,COF,OLED etc. the Aroma chemicals are used in advanced professional perfumery and Personal care & Household care industry.

Presently we have developed more than two hundred kind of performance single molecules, most of them are top quality and the cost is very reasonable and acceptable.in the fields of electronic chemicals and Aroma chemicals, we aim to play a qualified small role in the future manufacturing and supply chain.

Ixazomib (also known as MLN9708) is a type of cancer drug called a proteasome inhibitor.

Ixazomib is in the same class of drugs as bortezomib and is made by the same company, Takeda Oncology.

Ixazomib is considered to be a second-generation proteasome inhibitor because it has improved characteristics and activity over bortezomib.

Ixazomib is available as a pill whereas bortezomib is only available as an injection.
Ixazomib is an investigational oral proteasome inhibitor, which is being studied in multiple myeloma (MM), systemic light-chain (AL) amyloidosis and other malignancies. Ixazomib was granted orphan drug designation in MM in both the U.S. and Europe in 2011, and for AL amyloidosis in both the U.S. and Europe in 2012. It is the first oral proteasome inhibitor to enter Phase 3 clinical trials. Four global Phase 3 trials are ongoing:
Its appearance is white  powder solid . the purity (HPLC) is more than 99% , top quanlity, more competitive price, Special packing is offered.